OptimizeRx trades at a steep discount to peers, but strong AI-driven growth, rising cash flow and DAAP traction look encouraging.
They have a complicated one. Not the kind with obvious villains or clear-cut harm—the kind that's harder to explain. The home ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results